Meta-analysis of 8761 cases of stem cell therapy for osteoarthritis
- Moderna Latest Study: mRNA Therapy for Treating T Cell-Mediated Autoimmune Diseases
- The Biosecure Act May Hurt Pharmaceutical Supply Chains
- Mosquito Elimination on Global Health: Unraveling the Claim of 700K Annual Deaths
- Intensive Blood Pressure Management to Below 140 mmHg Reduces Stroke Risk, Regardless of Medication Dosage
- GLP-1 Drugs: How Significant is Their Impact on Brain Health?
- Why Eel Sashimi Is Unsafe: Understanding the Risks of Consuming Raw Eel
The Knee: Meta-analysis of 8761 cases of stem cell therapy for osteoarthritis
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The Knee: Meta-analysis of 8761 cases of stem cell therapy for osteoarthritis.
Stem Cell Therapy Approved! Meta-analysis of 8761 cases of stem cell therapy for osteoarthritis.
Mesenchymal stem cell preparations are effective in improving pain and function in patients with osteoarthritis, significantly better than other intra-articular injections.
In recent years, stem cells have made great progress in the treatment of osteoarthritis, and many new cell-based osteoarthritis drugs have been approved for marketing.
The indication is knee cartilage defect; since then, the stem cell drug Cartistem has been approved in South Korea for the treatment of degenerative arthritis and knee cartilage damage;
the stem cell drug Maci has been approved in the United States for the treatment of knee cartilage damage.
It can be seen from the listing and approval of the above-mentioned new drugs that stem cells have unlimited potential in the treatment of osteoarthritis, so what is the effect of stem cells on osteoarthritis?
Recently, a meta-analysis[1] published in “The Knee” compared the efficacy of different intra-articular injections in patients by systematically summarizing 79 randomized controlled clinical trials (including 8761 patients with knee osteoarthritis).
Ultimately, it concluded that stem cell injections had the greatest improvement in pain and function in patients with knee osteoarthritis at up to a year of follow-up
Osteoarthritis and Mesenchymal Stem Cell Therapy
Osteoarthritis (OA) is a degenerative joint disease that affects 30 million people in the United States alone, causing severe disability, reduced quality of life, and financial burden.
The knee joint is the most common site of OA, accounting for about 80% of all OA patients. Treatment options for OA include non-surgical and surgical treatments. Intra-articular injections (IA) remain a core component of non-surgical treatment modalities for OA because they provide short-term pain relief and improved joint function with a low risk of injury.
Several types of IA injections exist, including corticosteroids (CS), platelet-rich plasma (PRP), hyaluronic acid (HA), mesenchymal stem cell preparations, and others. Surgical treatment is joint replacement surgery, which is the last resort in OA treatment.
As a new type of intra-articular injection, mesenchymal stem cells have been widely studied.
A large number of preclinical and clinical studies on mesenchymal stem cells in the treatment of osteoarthritis have proved that cell therapy may be a feasible method for the treatment of osteoarthritis.
From the website, we found that there are currently more than 120 clinical registrations of mesenchymal stem cell therapy related to osteoarthritis.
Analysis of the effect of stem cells in the treatment of osteoarthritis
Meta-analyses are the highest level of evidence from clinical research and their results are feasible and high. In this analysis, the researchers searched the relevant literature and finally included 79 randomized controlled clinical trials (RCTs) including 8761 patients with knee osteoarthritis for analysis.
These randomized controlled clinical trials used intra-articular injections of different components (autologous conditioned serum, bone marrow concentrate, botulinum toxin, corticosteroids, hyaluronic acid, mesenchymal stem cells, vascular matrix components, etc.) in patients with knee osteoarthritis.
Treatment was followed by up to 1 year of follow-up to assess improvement in pain and improvement in motor and daily functional activities.
1. Assessment of pain improvement:
The visual analogue scale (VAS) was used to assess the degree of pain improvement, which is one of the most reliable and effective measurement tools for perceived pain in people aged 8 years and above.
The analysis found no significant difference in the VAS scores of the patients before receiving the different intra-articular injections.
After receiving the treatment, VAS scores were performed at 4-6 weeks, 3 months, 6 months, and 12 months, respectively.
The results showed that at each time point after the injection, the highest degree of pain improvement was received by the vascular matrix component (SVF). ) treated patients. (SVF is obtained from adipose tissue, and its main components are adipose-derived mesenchymal stem cells, etc.).
2. Assessment of functional activity improvement:
The functional activity improvement was assessed using the Western Ontario and McMaster University Osteoarthritis Index (WOMAC).
The analysis found no significant difference in WOMAC scores between the control group and any of the experimental groups before receiving treatment. Post-treatment, SVF-treated patients had the highest WOMAC score improvement at 12-month follow-up, although at 4-6 weeks, 3 months, and 6 months the highest improvement in WOMAC scores was observed in patients who were not treated with SVF , suggesting that SVF was long-lasting for patients with improved motor and daily functional activities. summary:
From the results of the meta-analysis, we can see that the mesenchymal stem cell preparation is effective in improving pain and function in patients with osteoarthritis, which is significantly better than other intra-articular injections.
However, this analysis also has shortcomings, such as a small number of included studies, missing study data, and differences among studies.
In the future, further and more in-depth basic research, as well as larger-scale clinical trials, and meta-analyses of more studies are still needed… In the hope that stem cells can make a greater contribution to the disease of osteoarthritis !
references:
[1] Anil U, Markus DH, Hurley ET, Manjunath AK, Alaia MJ, Campbell KA, Jazrawi LM, Strauss EJ. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: A network meta-analysis of randomized controlled trials. Knee. 2021 Oct;32:173-182.
https://pubmed.ncbi.nlm.nih.gov/34500430/
The Knee: Meta-analysis of 8761 cases of stem cell therapy for osteoarthritis
(sourceinternet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
